Linda C. Cummings

Linda C. Cummings

Auto-generated profile, based on publicly available information

Linda C. Cummings

Division of Gastroenterology and Liver Disease, Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2007 in Cancer
Verified
Journal Article
Open access
PDF file
LCLinda C. Cummings
Linda C. Cummings
JPJonathan D. Payes
Jonathan D. Payes
GCGregory S. Cooper
Gregory S. Cooper
BACKGROUND.: Hepatectomy is the standard of care for patients with colorectal cancer who have isolated hepatic metastases; however, the long‐term survival benefits of hepatectomy in this population have not been characterized well outside of case series. For the current study, a population‐based database was used to compare the survival of patients with liver metastases from colorectal cancer who did and did not undergo hepatectomy.METHODS.: Patients aged ≥65 years with incident colorectal cancer who were diagnosed from 1991 to 2001 were identified from the linked Surveillance, Epidemiology, and End Results (SEER)‐Medicare database. Liver metastasis diagnoses, colorectal resections, and hepatectomies were identified from hospital, outpatient, and physician‐supplier claims. Patients who did not undergo colorectal resection were excluded. Five‐year survival from the time of cancer diagnosis was determined by the Kaplan–Meier method. Cox proportional hazards models were used to evaluate survival.RESULTS.: Among 13,599 patients who were identified with incident colorectal cancer and liver metastases, 7673 patients (56.4%) presented with stage IV disease, and the remaining patients presented with earlier stage disease and developed subsequent metastases. Only 833 patients (6.1%) in the cohort underwent hepatic resection, and their 30‐day mortality rate was 4.3%. The 5‐year survival was 32.8% among patients who underwent hepatic resection, compared with 10.5% among patients who did not undergo hepatic resection (P < .0001), and better survival was observed in the subset of patients who presented initially with disease in stages I through III. In a Cox model, which was controlled for age, sex, race, comorbidities, and stage at presentation, lack of hepatic resection was associated with a 2.78‐fold increased risk of death.CONCLUSIONS.: Although hepatectomy rates among patients with colorectal cancer were low, hepatic resection was associated with improved survival. Cancer 2007 © 2007 American Cancer Society.

7 February 2012 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
LCLinda C Cummings
Linda C Cummings
CDConor P Delaney
Conor P Delaney
GCGregory S Cooper
Gregory S Cooper
Laparoscopic colectomy for colon cancer has been compared with open colectomy in randomized controlled trials, but these studies may not be generalizable because of strict enrollment and exclusion criteria which may explicitly or inadvertently exclude older individuals due to associated comorbidities. Previous studies of older patients undergoing laparoscopic colectomy have generally focused on short-term outcomes. The goals of this cohort study were to identify predictors of laparoscopic colectomy in an older population in the United States and to compare short-term and long-term outcomes.

1 August 2016 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
LCLinda C. Cummings
Linda C. Cummings
TKTzuyung Doug Kou
Tzuyung Doug Kou
MSMark D. Schluchter
Mark D. Schluchter
ACAmitabh Chak
Amitabh Chak
GCGregory S. Cooper
Gregory S. Cooper

1 January 2008 in Cancer Detection Prevention
Verified
Journal Article
Closed access
LCLinda C. Cummings
Linda C. Cummings
GCGregory S. Cooper
Gregory S. Cooper

11 October 2022 in American Journal of Gastroenterology
Verified
Journal Article
Open access
LCLinda C. Cummings
Linda C. Cummings
LHLeila Hojat
Leila Hojat
DNDavid C. Nguyen
David C. Nguyen
LSLisa Marie Stempak
Lisa Marie Stempak
DRDaniel D. Rhoads
Daniel D. Rhoads
NSNavid Sadri
Navid Sadri
INTRODUCTION: Increasing antimicrobial resistance with Helicobacter pylori infection has focused efforts to tailor eradication therapy based on identifying genetic markers of resistance to predict antimicrobial susceptibility. METHODS: In this retrospective study, we report the effect of routine inclusion of antimicrobial susceptibility testing and recommendations for eradication therapy with gastric specimens with H. pylori. RESULTS: The use of a recommended treatment regimen based on genetic markers of resistance was associated with an 84% rate of eradication success and 4.4 greater odds of eradication relative to unrecommended treatment. DISCUSSION: This is the first study describing the use of H. pylori genetic resistance testing as standard of care.

4 April 2022 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
LCLinda C. Cummings
Linda C. Cummings
CLChen Liang
Chen Liang
EMEdward J. Mascha
Edward J. Mascha
LSLeif Saager
Leif Saager
ZSZachary L. Smith
Zachary L. Smith
KCKenneth C. Cummings
Kenneth C. Cummings